Glimepiride, Metformin and Voglibose
Strength(s):
1 mg + 500 mg + 0.2 mg, 1 mg + 500 mg + 0.3 mg, 2 mg + 500 mg + 0.3 mg
Dosage
Form: Tablets
Description:
This triple combination targets multiple pathways in type 2 diabetes: Glimepiride enhances insulin secretion, Metformin reduces glucose production, and Voglibose delays carbohydrate absorption.
Key Features:
- Triple-action control for postprandial and fasting glucose
- Reduces the need for insulin therapy
- Ideal for patients with uncontrolled blood sugar
Precautions:
May cause gastrointestinal discomfort. Monitor renal function and liver enzymes regularly.